Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | Exploring the applications of CAR-Ts beyond hematology and oncology

Michael Hudecek • 2 Feb 2022
CAR-T Meeting 2022
General CAR-T

Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, discusses the potential of engineered immune cell therapies such as chimeric antigen receptor T-cells (CAR-Ts) in fields other than hematology and oncology, namely infectious diseases, auto-immune diseases, and cardiovascular diseases. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

More from Michael Hudecek

Accelerating CAR T-cell therapeutics with small molecules and CRISPR 2.0 gene editing
2:59
Accelerating CAR T-cell therapeutics with small molecules and CRISPR 2.0 gene editing
Michael Hudecek • 12 Apr 2025
CAR-T trials and research at UKW
1:50
CAR-T trials and research at UKW
Michael Hudecek • 2 Feb 2022
Young EBMT & EHA Ambassadors: the basic science behind CAR-Ts
1:16
Young EBMT & EHA Ambassadors: the basic science behind CAR-Ts
Michael Hudecek • 2 Feb 2022
EBMT-EHA CAR T-cell meeting: all the latest in CAR-T
2:23
EBMT-EHA CAR T-cell meeting: all the latest in CAR-T
Michael Hudecek • 2 Feb 2022

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals